Drug evaluation: tagatose in the treatment of type 2 diabetes and obesity.
- ISSN: 1472-4472 (Print)
- PubMed: 17086938
Spherix Inc (formerly Biospherics) is developing tagatose, an orally active lactose derivative for the potential treatment of obesity and type 2 diabetes. The compound is also under investigation for the potential treatment of anemia, hemophilia and medical problems related to infertility, birth weight and excessive maternal food intake. Phase I and II clinical trials have been completed.